AU7552696A - Apolipoprotein e2 and treatment of alzheimer's disease - Google Patents
Apolipoprotein e2 and treatment of alzheimer's diseaseInfo
- Publication number
- AU7552696A AU7552696A AU75526/96A AU7552696A AU7552696A AU 7552696 A AU7552696 A AU 7552696A AU 75526/96 A AU75526/96 A AU 75526/96A AU 7552696 A AU7552696 A AU 7552696A AU 7552696 A AU7552696 A AU 7552696A
- Authority
- AU
- Australia
- Prior art keywords
- apoe2
- apolipoprotein
- apoe
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010060219 Apolipoprotein E2 Proteins 0.000 title claims description 26
- 208000024827 Alzheimer disease Diseases 0.000 title description 14
- 101150037123 APOE gene Proteins 0.000 claims description 52
- 101100216294 Danio rerio apoeb gene Proteins 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 43
- 210000004556 brain Anatomy 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 102000007592 Apolipoproteins Human genes 0.000 claims description 6
- 108010071619 Apolipoproteins Proteins 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 108010091748 peptide A Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 claims 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 claims 1
- 238000011830 transgenic mouse model Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 241000710961 Semliki Forest virus Species 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 108010025628 Apolipoproteins E Proteins 0.000 description 6
- 102000013918 Apolipoproteins E Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 231100000219 mutagenic Toxicity 0.000 description 6
- 230000003505 mutagenic effect Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- -1 lecithin phospholipids Chemical class 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102100029470 Apolipoprotein E Human genes 0.000 description 4
- 101710095339 Apolipoprotein E Proteins 0.000 description 4
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 4
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 4
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 102000013498 tau Proteins Human genes 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 2
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 2
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 102000003669 Antiporters Human genes 0.000 description 1
- 108090000084 Antiporters Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000020887 hyperlipoproteinemia type 3 Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Description
- 1 -
APOLIPOPROTEIN E2 AND TREATMENT OF ALZHEIMER'S DISEASE
Field of the Invention This invention relates to recombinant DNA, protein purification, and Alzheimer's disease.
Background of the Invention Alzheimer's disease has two major neuropathological characteristics. The first is the presence of intraneuronal neurofibrillary tangles, the major protein component of which is hyperphosphorylated tau, a microtubule-associated protein. Electron microscopy shows neurofibrillary tangles to comprise paired helical filaments ("PHF") (Selkoe (1991) Neuron 6:487-498).
The second major characteristic is the presence of extracellular amyloid deposits in the brain. Amyloid deposits consist of polymers of the amyloid peptide A3, which is proteolytically derived from amyloid precursor protein ("APP").
Apolipoprotein E ("apoE") is a 34.2 kDa protein synthesized by the liver and various peripheral tissues, including kidney, adrenal gland, astrocytes and reticuloendothelial cells. ApoE is synthesized as precursor ("preapoE") with an 18-amino acid signal peptide. After the intracellular cleavage of the signal peptide, apoE is glycosylated with carbohydrate chains containing sialic acid and secreted as sialo apoE. It is subsequently desialated in plasma. For a discussion of apoE biosynthesis processing and other properties, see: Zannis et al. (1993) Adv. Hu . Genet. 21:145-319; Zannis et al. (1984) J. Biol. Chem. 259:5495-5499; and Zannis et al. (1986) J. Biol. Chem. 261:13415-13421.
Following synthesis, apoE is incorporated into lipoproteins and directs their catabolism, following recognition and binding by cell surface receptors. ApoE can be isolated from plasma and culture media of HepG-2 cells as a component of lipoprotein particles.
There are three common alleles that encode apoE in humans. The three alleles designated e4, e3, and e2 give rise to three homozygous phenotypes (i.e., E4/E4, E3/E3, and E2/E2) and three heterozygous phenotypes (i.e., E4/E3, E3/E2, and E4/E2) (Zannis and Breslow (1981)
Biochemistry 20:1033-1041; Zannis et al. (1981) Am. J. Hu . Genet. 33:11-24). The three different human apoE isoproteins, apoE4, apoE3, and apoE2, result from mutations at amino residues 112 and 158. ApoE4 contains Arg at position 112 and Arg at position 158. ApoE3 contains Cys at position 112, and Arg at position 158. ApoE2 contains Cys at positions 112 and 158.
Mutations in apoE which affect its recognition by the LDL receptor are associated with type III hyperlipoproteinemia and premature atherosclerosis. See, e.g., Goldstein et al. (1983) in: The Metabolic Basis of Inherited Disease (Stanbury et al., eds.), McGraw-Hill, New York, pp. 672-712. The apoE mutation which results in the apoE4 phenotype occurs with increased frequency in patients with late onset of Alzheimer's disease (Corder et al. (1993) Science 262:921-923). ApoE and Alzheimer's Disease
ApoE synthesis is increased following injury and is implicated in the growth and repair of the nervous system during development or after injury (Boyles et al. (1989)
J. Clin. Invest. 83:1015-1031). In the peripheral nervous system, the synthesis of apoE increases 250-350 fold within 3 weeks of sciatic nerve crush, and apoE constitutes 5% of the total soluble extracellular
protein. Recently, it has been shown that apoE is found in the brain lesions of AD patients and that the apoE4 phenotype predominates in patients with late onset familial AD (Corder et al. (1993) Science 262:921-923). It has been suggested that apoE is a risk factor and contributes to the pathogenesis of the disease. Two hypotheses have been advanced to explain the involvement of apoE in AD. The first hypothesis implies extracellular interaction of apoE with the 42 amino acid long amyloid peptide β (A/3) . Initial observations indicated that apoE from cerebrospinal fluid binds with high affinity to A3 (Wisniewski et al. (1993) Biochem. Biophys. Res. Commun. 192:359-365; Strittmatter et al. (1993) Proc. Natl. Acad. Sci. USA 90:1977-1981). In vitro experiments have shown that apoE can form a complex with A/3 peptide which is stable following boiling for 5 min at 2% SDS. Formation of stable complexes of apoE4 with A/3 is fast, compared to formation of complexes of apoE3 with A/3.
Electron microscopy studies showed that a combination of apoE4 with A/3 resulted in the formation of monofibrils 7 nm in diameter. The matrix of monofibrils formed with apoE4 was much denser than that with apoE3 (Sanan et al. (1994) J. Clin. Invest. 94:860-869).
A second hypothesis is that apoE3 binds to tau, and protects it from phosphorylation in the microtubule- binding domain, while apoE4 does not bind to tau (Strittmatter et al. (1994) Exper. Neurol. 125:163-171). As a result, tau gets hyperphosphorylated and can no longer bind efficiently and stabilize microtubules, leading to the formation of neurofibrillary tangles inside neurons.
Summary of the Invention We have discovered that glycosylated apolipoprotein E2 having a conformation which is the same as, or which closely approximates, its native
conformation, i.e., it is not denatured and then renatured, and exists in lipid-free as well as lipid- bound forms, binds to synthetic peptide amyloid peptide A/3 with a higher affinity than do apolipoproteins E3 and E4.
Accordingly, the invention features an isolated apolipoprotein E2 capable of specifically binding to amyloid peptide A3 with a higher affinity than apolipoproteins E3 or E4; the apolipoprotein E2 can be produced by (a) transforming a eukaryotic (preferably mammalian) host cell with DNA encoding apolipoprotein E2; (b) culturing the host cell; and (c) isolating the apolipoprotein E2 under non-denaturing conditions. As used herein, "apolipoprotein E2" refers both to the naturally-occurring amino sequence of the protein, and to variants in which there are one or more amino acid substitutions which do not substantially alter the conformation or other properties of the molecule. Examples of such mutant forms of E2 are given below in Table 1; these mutants not only retain native conformation when expressed in mammalian host cells, they exhibit superior binding properties compared to the native sequence.
Apolipoprotein E2 can be isolated under nondenaturing conditions by subjecting the growth medium from a culture of mammalian cells that express recombinant apolipoprotein E2 to cation exchange chromatography to produce an apolipoprotein E2-enriched cation exchange protein fraction, and then subjecting the resulting pool of apolipoprotein E2-enriched cation exchange fractions to anion exchange chromatography, thereby producing an anion exchange fraction highly enriched for apolipoprotein E2.
The invention also features a method for inhibiting the progression of Alzheimer's disease in a
patient with early onset Alzheimer's disease, or inhibiting the onset of Alzheimer's disease in a patient genetically at risk of developing Alzheimer's disease, by administering to the brain of the patient an effective amount of apolipoprotein E2 which is glycosylated, exists in lipid-free or lipid-bound forms, and has native or close to the native conformation produced by brain cells.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
Brief Description of the Drawings Fig. 1 is a schematic representation of the steps leading to production of plasmids of the invention.
Fig. 2 is a series of gel electrophoresis and autoradiography panels of apoE2 secretion from cells of the invention.
Fig. 3 is a series of panels illustrating apoE2, E3, and E4 expression by various cell types using the Semliki Forest Virus expression system. Fig. 4 is a pair of panels illustrating apoE expression in a bioreactor setting.
Fig. 5 is a set of panels showing elution profiles of apoE from ion exchange columns.
Fig. 6 is a set of panels showing binding to A/3 of apolipoprotein E obtained by expression in eukaryotic cells. The apoE experiment shows that the ability of apolipoprotein E produced by eukaryotic cells to bind to Aβ follows the order: apolipoprotein E2 > apolipoprotein E3 > apolipoprotein E4. Fig. 7 is a set of panels showing binding to Aβ of apolipoprotein E3 and apolipoprotein E4 obtained by the baculovirus expression system. The ability of apoE3 and apoE4 forms thus obtained to bind to A/3 is different from that of apoE expressed by eukaryotic cells (Fig. 6) .
Fig. 8 is a set of panels showing binding to A/3 of VLDL, apoE3 and apoE4. The ability of apoE3 and apoE4 forms thus obtained to bind to A/3 is different from that of apoE expressed by eukaryotic cells (Fig. 6) . Fig. 9 is a panel showing distribution of apolipoprotein E secreted by C127 cells to lipid-free and lipid-bound forms.
Fig. 10 is a diagram predicting binding of apolipoprotein E2 derivatives obtained from eukaryotic cells to A/3 which differ from the binding of naturally occurring apolipoproteins E3, E4 and native-sequence E2.
Detailed Description
The present invention provides recombinant apolipoprotein E2 in its native conformation. Because of its native conformation, the apoE2 of the invention binds to the Aβ peptide with greater affinity than apoE3 or apoE4.
Generation of cell lines of C127 cells expressing apoE2. apoE3 and apoE4. We have generated a recombinant C127 cell line that secretes apoE2. This cell line has been generated as follows: The apoE cDNA we isolated previously (Zannis et al. (1984) J. Biol. Chem. 259:5495), amplified and mutagenized by PCR, was excised, with nucleases Aatll and Drall, from the original plasmid, and subcloned into the Smal site of the pUC19 plasmid to produce the pUC-E3 derivative. This was followed by excision of the apoE DNA with BamHl and Bglll. The pUC-E3 plasmid was amplified and mutagenized by PCR as described in Fig. IA, using a set of 5' and 3' amplification primers and a set of mutagenic primers. The mutagenic primers were designed to replace Cys-112 with Arg, and to replace Arg- 158 with Cys.
The 5' external amplification primer extended from nucleotides 223 to 241 of the apoE gene (sequence numbering of Karathanassis, Haddad, Salmon and Zannis, Biochemistry and Biology of Plasma Lipoproteins 1985, pp. 475-493). The 3' external amplification primer extended between nucleotides 1102-1082 in the 3' region of the cDNA. One set of mutagenic sense and antisense oligonucleotides covered codons 154-161 (nucleotides 576- 595) for alteration of Arg-158 to Cys-158 in order to produce apoE2. Another set of mutagenic sense and antisense oligonucleotides covered codons 108-113 (nucleotides 438-457) for the change of Cys-112 to Arg-112 in order to produce apoE4.
For alteration of Arg-158→Cys, two separate amplifications were utilized. The first utilized the 5' external primer and the antisense mutagenic primer covering codon 158. The second utilized the 3' external primer and the sense mutagenic primer covering codon 158. An aliquot of 4% from each reaction was mixed and amplified with the 5' and 3' external primers. The amplified fragment containing the Arg-158→Cys mutation was used to replace the corresponding region in the pUC- E3 plasmid, as shown in Fig. IA, giving rise to pUC-E2 plasmid. Similarly, the amplified fragment containing the Cys-112→Arg mutation was used to replace the corresponding region of the pUC- E3 plasmid, as shown in Fig. IA, giving rise to pUC-E4 plasmid (Fig. IA) .
The DNA insert obtained from the pUC-E2 derivative was initially cloned into the BamHl site of the pcDNA under the control of the CMV pcDNA promoter or into the BamHl and Bglll site of Semliki Forest Virus vector (pSFV) to generate the pcDNA-E2 derivative and the pSFV- E2 derivatives. The apoE2 insert was then excised from the pUC-E2 derivative, blunt-ended with the Klenow
fragment of the DNA polymerase I, and ligated to Xhol linkers digested with Xhol and cloned into the Xhol site of pBMT3X vector to generate pBMT3X-E2, expression plasmid (Fig. IB) . A similar approach was utilized to generate the pBMT3X-E3 and E4 plasmids.
The pBMT3X is a bovine papilloma virus-based vector in which the gene of interest is transcribed under the control of the mouse metallothionein I promoter. The vector also contains the human metallothionein I gene, which confers resistance to 10 μM CdCl2 (Cladaras et al. (1987) J. Biol. Chem. 262:2310-2315).
To generate stable cell lines expressing apoE2, cells were transfected with the pBMT3X-apoE2 expression plasmid by the Calcium Phosphate DNA co-precipitation method (Graham and van der Eb (1973) Virology 52:456). Permanent cell lines were selected for their resistance to lOμM CdCl2. Resistant colonies were isolated with cloning cylinders and grown to 90% confluency.
To characterize the protein secreted by this cell line, the cell line was labelled with 35S-methionine for 2 hours. Media and cell lysates were immunoprecipitated with rabbit anti-apoE, mixed with 15 μg HDL containing apoE3, and analyzed with two-dimensional gel electrophoresis (PAGE) and autoradiography. In this analysis, proteins are separated on the basis of their charge by isoelectric focusing and on the basis of their size by SDS-PAGE.
The gel obtained from this analysis showed the position of the marker plasma apoE3 (Fig. 2A,B,C) , and the autoradiogram showed the position of the newly synthesized apoE2 protein (Fig. 2A',B',C). Superimposition of the gel on the autoradiogram established the charge and size differences between the plasma apoE3 and the newly synthesized protein (Fig. 2A",B",C") . This analysis, shown in Figs. 2A-C",
established that the newly synthesized apoE2 is more acidic by one and two positive charges than apoE3 and apoE4, respectively. The analysis also shows that the secreted protein is extensively modified and resembles the protein synthesized by hepatic and other types of cells (Zannis et al. (1986) J. Biol. Chem. 261:13415- 13421) .
We have also expressed the apoE2 in Cos-1 cells using the pcDNA vectors under the control of the CMV promoter.
Expression of ApoE cDNA Using the Semliki Forest Virus Expression System
In addition to apoE2 expression in C127 cells, de¬ scribed above, we have also used other eukaryotic expression systems for expression of apoE2, apoE3 and apoE4 based on Semliki Forest Virus (SFV) replicon. These systems consist of two plasmids - pSFVl and pSFV- helper-2. The first plasmid represents the cDNA copy of Semliki Forest Virus genome with a deleted subgenomic (26S) coding region for the structural proteins of the virus, followed by a cassette of polylinker (BamHl-X al- Smal) and translational stop codons in all three reading frames. The cDNA of human apoE2 was cut with Bglll and BamHl, present in the polylinker region of pSFV, and inserted via a BamHl Bglll site to create vector pSFV apoE2. In this vector, apoE2 cDNA expression is driven by the 26S promoter in the context of SFV genome. The second plasmid is pSFV-helper 2, which retains the 5' and 3' signals needed for RNA replication, as well as the complete structural region, including its promoter, but which lacks a region required for packaging of SFV RNA into nucleocapsids.
The pivotal step in the development of the pSFV expression system is helper catalyzed packaging of
pSFVcE2 RNA. The system allows rapid transient expression of apoE2 cDNA mutants, allowing fast testing of their functions, physicochemical properties, and neuronal toxicity. Initially, plasmid pSFV apoE2, or pSFV-helper 2 was transcribed in vitro under the control of an SP6 promoter. Both SFV apoE2 and SFV-helper 2 RNAs were then cotransfected by electroporation into BHK cells. In the electroporated cells, the SFV apoE2 RNA encodes the enzymes for RNA replication (amplification) and transcription, whereas SFV helper 2 RNA supports the production of the structural proteins via its subgenomic region. Since the helper lacks the region required for RNA packaging, RNA derived from this vector will not be packaged. Thus, transfections with recombinant and helper RNA produce only virus particles that carry recombinant RNA.
The viruses produced provide a one-round virus stock. After infection of cells with the recombinant virus, the cells will only express the heterologous protein (apoE2) . This virus stock was utilized to infect BHK cells or primary astrocytes obtained from mice deficient in apoE. For this analysis, confluent BHK cells or apoE deficient mouse primary astrocyte cultures were infected with recombinant SFV apoE2, virus at multiplici¬ ty of infection of approximately three infective units per cell for 12 hrs and grown in serum-free BHK medium for 24 h. The viral titer was estimated between IO7 and IO8 infectious units/ml. Aliquots of 50 μl medium were removed and analyzed by SDS-PAGE and immunoblotting (Fig. 3) . The above description demonstrates that recombinant, glycosylated apoE2 can be efficiently produced in a variety of eukaryotic cells. The level of expression estimated from the intensity of the stained bands is approximately 5-10 μg apoE/106 cells/1 ml/24 hrs.
Apolipoprotein E4 and Apolipoprotein E3 Were Expressed in a Similar Way Using the SFV Expression Svstem.
Large-scale Growth of APOE2 Producing Cells in Bioreactors (Verax System 10) The Verax bioreactors consist of a vertical column containing microspheres in suspension (Fig. 4A) . The microspheres are made of collagen and are hollow with a pore diameter which allows cell attachment and growth. Cell densities of IO8 cells/ml are achieved. The microspheres are kept in suspension by the flow of incoming culture medium. A gas exchange unit provides the required 02 and removes excess C02. Temperature control keeps the medium at 37°C. The medium is circulated by a pump through the bioreactor and the gas exchange unit. Using the Verax System-10 Bioreactors the culture medium contain 30-50 μg apoE/ml (Fig. 4B) .
The medium of C127 cells expressing apoE2, apoE3 or apoE4 was purified by a scheme employing a dextran sulfate sepharose column and DEAE sepharose column frac- tionation.
Briefly, a 20 ml dextran sulfate-sepharose column was equilibrated with 20 mM Tris-HCl, 0.2 M NaCl, pH 7.4. A total of 1 liter of apoE-containing culture medium was adjusted to 0.2 M NaCl and loaded on the column at a flow rate of ~80 ml/hr. The column was washed with 200 ml of 20 mM Tris-HCl, 0.2 M NaCl, pH 7.4 at the same flow rate. The column was eluted with a 120 ml 0.2-1.0 M NaCl gradient in 20 mM Tris-HCl, pH 7.4 at the same flow rate; fractions of 2 ml were collected. The apoE-containing samples eluted from the dextran sulfate sepharose column were adjusted to 50 mM NaCl by dilution with 20 mM Tris- HCl pH 7.4 and were loaded on a 10 ml DEAE column. The column was eluted with 70 ml of 0.05-0.75 M NaCl gradient in 20 mM Tris-HCl pH 7.4.
Properties of Apolipoproteins E3, E4 and E2 Produced by Mammalian Cells and Other Sources.
Binding of APOE2. APOE3 and APOE4 Produced bv Cell Cultures to the Synthetic Amyloid Peptide Aβ. For this analysis, 1 μg of apoE2 or apoE3 or apoE4 was diluted with 9 μl H20 containing either 0 or 4 μM Aβ (40 amino acid residues in length) in 20 mM tris pH 8.0 buffer and incubated at 25°C for 12 hrs. Incubation was terminated by adding equal volume 2X Laemmli buffer (4% SDS without β-mercaptoethanol) and boiling for 5 min. The mixture was analyzed by gel electrophoresis in two gels (10% polyacrylamide - 2% SDS) and Western blotting. After blotting one of the filters (Panel A) was treated with mouse monoclonal antibody against A/3 (Fig. 6A) and the other two panels (Panels B&C) with goat polyclonal antibody against apoE.
This experiment shows that recombinant apoE2, apoE3 and apoE4 form stable diffused complexes with Aβ in solution (Fig. 6A) . Each such complex is stable following boiling in 2% SDS. The diffused nature of the complex may result from the fact that apoE produced by these cell lines is highly modified with carbohydrate chains containing sialic acid. There is no formation of complexes with higher Mr with any of the isoforms. The formation of complexes can be seen also in the first three lanes of Fig. 6B in lane 4 which do not contain AS. In this experiment equal quantities of apoE (1 μg) and Aβ (4 μg) were utilized for all the isoforms. The analyses of Fig. 6A-C show that the ability of apoE produced by these cells to bind to Aβ follows the order apoE2>apoE3>apoE4. Similar results are obtained with apoE produced by apoE produced by the different expression systems described before. This binding behavior of apoE is different from that of apoE produced by the baculovirus expression system (Fig. 7) or VLDL (Fig. 8)
(Strittmatter et al. (1993) Proc. Natl. Acad. Sci. USA 90:8098-8102ι .
The experiments of Fig. 6A-C show that recombinant apoE2, apoE3 and apoE4 form stable complexes with Aβ. These complexes are visible in the first three lanes of Fig. 6A,B, which contain Aβ but not in the corresponding lanes of Fig. 6C, which does not contain Aβ. This analysis establishes unequivocally that the binding of newly synthesized apoE secreted into the cell medium which consist mostly of modified forms of apoE with A/3 follows the order apoE2>apoE3>apoE4.
In other experiments we have analyzed the apoE secreted by cell cultures by density gradient ultracentrifugation and immunoblotting. This analysis showed that approximately 45% of apoE is distributed in lipoprotein particles which float in the HDL region in d=1.08-1.20 g/ml, 40% in lipid-poor particles which float in the d=1.22-1.28 g/ml region, and 15% in a lipid-free fraction d>1.33 g/ml (Fig. 9). These different types of particles participate to different degrees in the formation of complexes with A/S.
According to epidemiological data (Corder et al. (1993) Science 262:921) and the findings of Fig. 6A-C, increased binding of apoE isoforms to A/3 correlates negatively with the risk of developing Alzheimer's disease. Derivatives of apoE2 generated by in vitro mutagenesis containing one or more amino acid substitutions which do not substantially alter the conformation or other properties of the molecule may surpass the ability of the naturally occurring apoE2 form to bind A/8. These derivatives (examples are shown in Table 1) will provide a series of experimental points to assess the binding behavior of apoE (Fig. 10) . Taking into account the reported progress in the generation of an animal model of AD (Gomes et al. (1995) Nature
373:523), one approach to further establish the relationship between the binding of apoE to A/8 and AD will be as follows: mice expressing natural or mutant apoE forms in an apoE deficient background (Plum et al. (1992) Cell 71:343-353) will be mated with the AD-prone mouse generated by Athena Neuroscience (Gomes et al. (1995) Nature 373:523). Analysis of the offspring will provide information as to whether a specific apoE variant protects or accelerates the development of the AD phenotype in relationship to the parent AD mouse. For instance, crossing of the AD prone mouse with the EX1 or EX6 mouse will confirm that strong binding of apoE to Aβ is beneficial and weak binding is detrimental. If strong binding is beneficial, we will anticipate that the EX6 form will protect from AD when it is introduced into the AD-prone mouse, whereas EX1 will accelerate the development of AD.
Formulation and Administration
To be effective, the apoE2 of the invention should come in contact with neuronal cells of the brain, or with the physiological fluids in the immediate vicinity of such cells. The apoE2, in that environment, binds to the Aβ- a yloid peptide, or to /3-amyloid precursor protein; when it binds to precursor protein; it prevents the precursor from progressing to the next stage, which is cleavage to form the fl-amyloid protein characteristic of Alzheimer's disease. When apoE2 binds to A/3-amyloid peptide, such binding inhibits progression of Alzheimer's disease by preventing formation of the extracellular amyloid plaques.
Generally, there are several approaches to bring apoE2 into contact with brain cells or to remove A/3 from the brain.
It has been shown that noncovalent association of apoE with lecithin phospholipids leads to the formation of discoidal particles (Innerarity et al. (1979) J. Biol. Chem. 254:4186-4190). ApoE also associates with triglyceride-rich phospholipid emulsions (Derksen and Small (1989) Biochemistry 28:900-906).
In one method, apoE2 produced by eukaryotic cells will be administered into the ventricles of the brain and will enter into the cerebrospinal fluid where it will be bound to A/3.
In another method, apoE2 phospholipid vesicles or triglyceride phospholipid emulsion will be administered into the ventricles of the brain. The A/3 will bind to the vesicles or the emulsions and will be removed from the brain.
In a third method, apoE2 phospholipid vesicles or the triglyceride phospholipid emulsions will be administered intravenously. The complexes will cross the blood/brain barrier by interactions with the apoE receptor present in the blood/brain barrier.
In a fourth method, biotinylated polyamides will be conjugated to streptavidin conjugated apoE2 according to Partridge et al. (1995) Proc. Natl. Acad. Sci. USA 92:5592-5596). Following intravenous administration, the complex will cross the blood/brain barrier by interaction with the apoE receptor present in blood brain barrier.
Free apoE2 or apoE2 associated with lipids can be administered to the ventricle of the brain by means of a stereotaxic instrument which is commercially available. The stereotaxic coordinates of the insertion point on the skull is marked by a sterile pencil. A hole of 2-3 mm is made in the skull. The dura is punctured and is covered with saline soaked gel-foam using the stereotaxic holder, and a thin tube is lowered into the ventricle and is connected with the infusion pump that will deliver the
- 16 - apoE2 in lipid-free or lipid-bound form into the ventricle.
The apoE2 solution or apoE2 phospholipid vesicles or apoE2 triglyceride phospholipid emulsions are loaded into the intraventricular pump, which has been implanted into the patient by known techniques. Each apoE2 preparation is continuously infused into the ventricle of the patient's brain, at a rate sufficient to deliver 500 to 1000 μg of protein per 75 kg body weight of the patient per day.
Another mode of administration is to inject the protein, dissolved in a carrier liquid, into the spinal column of the patient so that it contacts the patient's cerebrospinal fluid. Another mode of administration is intravenous injection of apoE2 phospholipid vesicles or apoE2 triglyceride phospholipid emulsions or conjugates of apoE2 with polyamides in physiological solutions containing 2 mg apoE2/ml. Ten mis of apoE2-containing solution will be injected twice per day.
Generally, the apoE2 of the invention can be administered to three classes of patients:
1. Patients who have been diagnosed with Alzheimer's disease, and who are exhibiting moderate to severe symptoms of the disease;
2. Patients who are exhibiting early-stage symptoms of Alzheimer's disease, and who are therefore suspected of having the disease; and
3. Asymptomatic patients who are over the age of 45 and who have a family history of Alzheimer's disease; one class of such patients are those carrying two copies of the apoE4 gene.
An alternative method of treatment is to administer DNA encoding apoE2 rather than apoE2 to protein. This gene therapy method is preferably carried
out using either a retroviral vector or an expression vector containing apoE2- encoding DNA, suspended in a liquid carrier; the suspension is administered either to the cerebrospinal fluid or the brain ventricle in the same manner that the protein in solution is administered. Suitable plasmid and retroviral vectors are well known and publicly and commercially available.
Other embodiments are within the following claims, What is claimed is:
Claims (11)
- Claims 1. Recombinant apolipoprotein E2 (apoE2) which binds to amyloid peptide A/8 or to amyloid β precursor protein.
- 2. The apoE2 of claim 1 wherein said apoE2 has a higher affinity for Aβ than do apolipoproteins E3 and E4.
- 3. The apoE2 of claim 1, having one of the amino acid sequences shown in Table 1.
- 4. The apoE2 of claim 3 wherein said apoE2 has a higher affinity for Aβ than does the native-sequence form of apolipoprotein E2.
- 5. The apoE2 of claim 1 wherein said apoE2 is glycosylated and is produced by the process of(a) transforming a eukaryotic host cell with DNA encoding apolipoprotein E2,(b) culturing said host cell in a growth medium, and(c) isolating said apolipoprotein E2 under non-denaturing conditions.
- 6. The apoE2 of claim 3 wherein said eukaryotic host cell is a mammalian cell.
- 7. The recombinant apolipoprotein E2 of claim 1, wherein Cys 112 of the native molecule is replaced with Arg.
- 8. A recombinant mammalian cell that expresses recombinant apolipoprotein E2.
- 9. The cell of claim 8, wherein said apolipoprotein E2 binds to amyloid peptide A/8 with a higher affinity than do apolipoproteins E3 and E4.
- 10. The cell line of claim 8, wherein said apolipoprotein E2 has a non-native amino acid sequence and binds to amyloid peptide A/3 with higher affinity than does native-sequence apoE2.
- 11. A transgenic mouse having an apoE-deficient background, wherein said mouse expresses human apoE2 in neurons of its brain.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55172295A | 1995-11-01 | 1995-11-01 | |
US08/551722 | 1995-11-01 | ||
PCT/US1996/017629 WO1997016458A1 (en) | 1995-11-01 | 1996-10-31 | Apolipoprotein e2 and treatment of alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
AU7552696A true AU7552696A (en) | 1997-05-22 |
AU720446B2 AU720446B2 (en) | 2000-06-01 |
Family
ID=24202413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU75526/96A Ceased AU720446B2 (en) | 1995-11-01 | 1996-10-31 | Apolipoprotein E2 and treatment of Alzheimer's disease |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0866799A4 (en) |
JP (1) | JP2000500332A (en) |
AU (1) | AU720446B2 (en) |
BR (1) | BR9611329A (en) |
CA (1) | CA2236274A1 (en) |
MX (1) | MX9803422A (en) |
WO (1) | WO1997016458A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6234099A (en) * | 1998-10-16 | 2000-05-08 | Introgene B.V. | Gene therapy of alzheimer's disease by delivery of an encoded apoliprotein |
JP2002530122A (en) * | 1998-11-25 | 2002-09-17 | サイオス インコーポレイテッド | Prevention and treatment of amyloid-related diseases |
CN1315402A (en) * | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | Polypeptide-human amyloid precursor protein bindin 14 and polynucleotide for coding it |
CN1315439A (en) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | Polypeptide-human amyloid precursor protein bindin 9 and polynucleotide for coding it |
EP1670517A1 (en) * | 2003-09-26 | 2006-06-21 | Eli Lilly And Company | Lentiviral apoe2 gene therapy |
EP1991252A2 (en) * | 2006-02-21 | 2008-11-19 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
WO2010020822A1 (en) * | 2008-08-19 | 2010-02-25 | University Of Patras | Therapy for apolipoprotein-induced hypertriglyceridemia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU587989B2 (en) * | 1984-10-16 | 1989-09-07 | Mitsubishi Chemical Corporation | DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins |
GB9414624D0 (en) * | 1994-07-20 | 1994-09-07 | Smithkline Beecham Plc | Novel method |
-
1996
- 1996-10-31 EP EP96937887A patent/EP0866799A4/en not_active Withdrawn
- 1996-10-31 JP JP9517597A patent/JP2000500332A/en not_active Ceased
- 1996-10-31 WO PCT/US1996/017629 patent/WO1997016458A1/en not_active Application Discontinuation
- 1996-10-31 AU AU75526/96A patent/AU720446B2/en not_active Ceased
- 1996-10-31 BR BR9611329-4A patent/BR9611329A/en not_active Application Discontinuation
- 1996-10-31 CA CA 2236274 patent/CA2236274A1/en not_active Abandoned
-
1998
- 1998-04-30 MX MX9803422A patent/MX9803422A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU720446B2 (en) | 2000-06-01 |
EP0866799A1 (en) | 1998-09-30 |
CA2236274A1 (en) | 1997-05-09 |
JP2000500332A (en) | 2000-01-18 |
BR9611329A (en) | 1999-12-28 |
WO1997016458A1 (en) | 1997-05-09 |
EP0866799A4 (en) | 2000-08-23 |
MX9803422A (en) | 1998-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CALERO et al. | Functional and structural properties of lipid-associated apolipoprotein J (clusterin) | |
JP2525438B2 (en) | Factor-8: C manufacturing method | |
US5958893A (en) | Genes and proteins for treating cystic fibrosis | |
EP0446017A1 (en) | New diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator | |
US5674898A (en) | Methods and therapeutic compositions for treating cystic fibrosis | |
US5525472A (en) | Method for production and purification or recombinant Apolipoprotein E from bacteria | |
CA1316132C (en) | Cdna and gene for human angiogenin (angiogenesis factor) and method of expression | |
EP0239631A1 (en) | Recombinant apolipoproteins and methods | |
SG192693A1 (en) | Lipoprotein complexes and manufacturing and uses thereof | |
Li et al. | Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain | |
AU720446B2 (en) | Apolipoprotein E2 and treatment of Alzheimer's disease | |
US4943527A (en) | Mature apoai protein production under serum free culturing conditions | |
JP2009171980A (en) | Compound and method for lowering cholesterol level without inducing hypertriglyceridemia | |
CN1206421A (en) | Apolipoprotein Ez and treatment of alzheimer's disease | |
US20060142200A1 (en) | Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia | |
US20070053879A1 (en) | Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator | |
TW202146040A (en) | Animal models of lipid metabolism and methods of treating hyperlipidemia or hyperlipidemia-related diseases | |
US7118911B1 (en) | DNA molecules stabilized for propagation in bacterial cells that encode cystic fibrosis transmembrane conductance regulator | |
Davis | Molecular and cell biology of cystic fibrosis | |
EP0600875A4 (en) | Purification of recombinant apolipoprotein e from bacteria. | |
Knouff | Lipoprotein clearance in mouse models of the apolipoprotein E polymorphism | |
Cvetkovic | Apolipoprotein E: Mediated Effects on Neuron Growth | |
CA2436259A1 (en) | Compounds effecting neuron remodeling and assays for same | |
Xu | Characterization of the endothelial cell protein C receptor | |
Laccotripe | Structural and functional analysis of human apolipoprotein AI |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |